It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...